Precision medicine in early-onset epilepsy: the KCNQ2 paradigm

Abstract

The identification of the genetic causes and the underlying pathogenic mechanisms in early-onset epilepsies has proved to be essential in improving the efficacy of therapeutic decisions and the overall patient management, especially in the era of precision medicine. We report an infant presenting with a cluster of focal motor seizures with autonomic manifestations at day 3 of life. Electroencephalograms showed multifocal epileptic abnormalities and a burst-suppression pattern. Neurological examination showed poor visual fixation and hypotonia. Neuroimaging was normal. Seizures remitted with phenytoin and were well-controlled after the switch to oral carbamazepine. In the hypothesis of a genetic etiology, next-generation sequencing panel for epileptic encephalopathies was performed and identified a de novo missense mutation in KCNQ2: c.1742G>A; p.(Arg581Gln) (NM_172107.2). This case report highlights the importance of the early recognition of the electroclinical phenotype and the detection of the underlying genetic cause in the implementation of “tailored” therapies in early-onset genetic epilepsies.

Keywords

KCNQ2 / early-onset epilepsy / developmental and epileptic encephalopathy / next-generation sequencing / precision medicine / sodium channel blockers

References

[1] OrsiniA,StrianoP.Recent advances in epilepsy genetics..Neurosci Lett2018;667:4-9

[2] HildebrandMS,DamianoJA,SchefferIE.Recent advances in the molecular genetics of epilepsy..J Med Genet2013;50:271-9

[3] CornetM.Genetics of neonatal-onset epilepsies. Neonatal Neurology.2019;Elsevier415-33

[4] GlassHC,WusthoffCJ,AbendNS.Contemporary profile of seizures in neonates: a prospective cohort study..J Pediatr2016;174:98-103.e1 PMCID:PMC4925241

[5] SymondsJD,StewartK,O’ReganM.Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort..Brain2019;142:2303-18 PMCID:PMC6658850

[6] MiceliF,JoshiN,CooperE.AdamMP,PagonRA,BeanLJH.KCNQ2-Related disorders..GeneReviews® [Internet].1993-2020;Seattle (WA)University of Washington, Seattle

[7] MillichapJJ,TsuchidaT,CarmantL.KCNQ2 encephalopathy: features, mutational hot spots, and ezogabine treatment of 11 patients..Neurol Genet2016;2:e96 PMCID:PMC4995058

[8] StrianoP.From genetic testing to precision medicine in epilepsy..Neurotherapeutics2020;17:609-15 PMCID:PMC7283411

[9] KuerstenM,GerstlL,StülpnagelCV.Antiepileptic therapy approaches in KCNQ2 related epilepsy: a systematic review..Eur J Med Genet2020;63:103628

[10] BiervertC,KubischC,ProppingP.A potassium channel mutation in neonatal human epilepsy..Science1998;279:403-6

[11] OrhanG,SchepersD,ReichelSN.Dominant-negative effects of KCNQ2 mutations are associated with epileptic encephalopathy..Ann Neurol2014;75:382-94

[12] GotoA,ShibataM,CooperEC.Characteristics of KCNQ2 variants causing either benign neonatal epilepsy or developmental and epileptic encephalopathy..Epilepsia2019;60:1870-80

[13] CornetMC,CilioMR.Neonatal epilepsies: clinical management..Semin Fetal Neonatal Med2018;23:204-12

[14] VilanA,StrianoP,WeekeLC.A distinctive ictal amplitude-integrated electroencephalography pattern in newborns with neonatal epilepsy associated with KCNQ2 mutations..Neonatology2017;112:387-93

[15] ScalaM,BisulliF,EliaM.Advances in genetic testing and optimization of clinical management in children and adults with epilepsy..Expert Rev Neurother2020;20:251-69

[16] DilenaR,Di CapuaM,CapovillaG.Influence of etiology on treatment choices for neonatal seizures: a survey among pediatric neurologists..Brain Dev2019;41:595-9

[17] NumisAL,SullivanJE,StrianoP.KCNQ2 encephalopathy: delineation of the electroclinical phenotype and treatment response..Neurology2014;82:368-70 PMCID:PMC3929196

[18] SchefferIE,CapovillaG,FrenchJ.ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology..Epilepsia2017;58:512-21 PMCID:PMC5386840

[19] Schubert-BastS,FischerD,RamantaniG.Sodium channel blockers in KCNQ2-encephalopathy: Lacosamide as a new treatment option..Seizure2017;51:171-3

[20] ReifPS,HelbigI,KleinKM.Precision medicine in genetic epilepsies: break of dawn?.Expert Rev Neurother2017;17:381-92

[21] KlotzKA,KorinthenbergR.Vitamin B6-responsive epilepsy due to a novel KCNQ2 mutation..Neuropediatrics2017;48:199-204